Real-time insights. Smarter decisions. Better trades.
š Search Stocks 14 day Free Trial
PRO MEDICUS LIMITED (PME)ASX AI Signals has generated 0 signals for PME during the last 90 days, indicating low trading activity
PME Share Price | |
| Current Price | $209.650 |
| 52 Week High | $329.235 |
| 52 Week Low: | $107.852 |
| Trading at (% of 52 Week High) | 63.68% |
Pro Medicus Limited (ASX: PME) is an Australian healthcare technology company that develops and sells innovative medical imaging software. Its products help hospitals and radiologists improve the efficiency and accuracy of diagnostic imaging workflows. The company serves clients globally, including major healthcare providers and imaging centers.
The Health Care Equipment & Services sector on the ASX includes companies that produce medical devices, equipment, and supplies, as well as those providing healthcare-related services. This sector covers a wide range of products such as surgical instruments, diagnostic machines, and health monitoring devices. It also includes businesses involved in healthcare management, medical laboratories, and support services. These companies play a key role in supporting hospitals, clinics, and other healthcare providers to improve patient care. The sector is influenced by factors like technological advances, regulatory changes, and demand for healthcare services.
Pro Medicus Ltd (PME) demonstrates strong market positioning in medical imaging software with consistent revenue growth and expanding international footprint. The current price reflects solid fundamentals and positive AI-driven buy signals, supported by robust demand in healthcare IT solutions.
Visage releases native Visage 7 | Reporting
SAN DIEGO, June 8, 2026 /PRNewswire/ -- Visage Imaging, Inc. ("Visage"), a wholly owned subsidiary of Pro MedicusĀ Ltd. (ASX:Ā PME), has announced it will demonstrate the unmatched value of One Platformā¢, showcasing the complete set of capabilities and late The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even companies that have no revenue, no profit, and a record of falling short, can manage to find investors. But as Peter Lynch said in One Up On Wall Street, 'Long shots almost never pay of Visage releases Visage 7.1.20, including Visage 7 Web and Visage Chat+
SAN DIEGO, March 10, 2026 /PRNewswire/ -- Visage Imaging, Inc. ("Visage"), a wholly owned subsidiary of ProĀ MedicusĀ Ltd. (ASX:Ā PME), has announced it will highlight a series of released innovations for the industry-leading Visag Visage introduces Visage 7 | Digital Pathology and AI innovations
SAN DIEGO, Nov. 19, 2025 /PRNewswire/ -- Visage Imaging, Inc. ("Visage"), a wholly owned subsidiary of ProĀ MedicusĀ Ltd. (ASX:Ā PME), has announced it will showcase a series of new innovations and events for the industry-leading Visage As Australian shares brace for a challenging day with the ASX 200 futures indicating a significant drop, the market sentiment has been further unsettled by both domestic political shifts and international economic disruptions. In this climate, identifying high growth tech stocks requires careful conLatest PRO MEDICUS LIMITED(PME) News
Visage Highlights One Platform AI-Optimized at SIIM26
Is Now The Time To Put Pro Medicus (ASX:PME) On Your Watchlist?
Visage Elevates AI Optimized Enterprise Imaging at HIMSS26
Visage Propels AI Optimized Enterprise Imaging at RSNA 2025
Exploring High Growth Tech Stocks in Australia This November 2025
Get access to daily BUY & SELL signals, advanced AI analysis, watchlists and email alerts.
14 Day Free Trial ā¢ Cancel Anytime ā¢ Founders Price $15/month
Start My Free Trial